Search results for "1310"

showing 3 items of 13 documents

Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement

2020

Genome sequencing and gene-based therapies appear poised to advance the management of rare lipoprotein disorders and associated dyslipidaemias. However, in practice, underdiagnosis and undertreatment of these disorders are common, in large part due to interindividual variability in the genetic causes and phenotypic presentation of these conditions. To address these challenges, the European Atherosclerosis Society formed a task force to provide practical clinical guidance focusing on patients with extreme concentrations (either low or high) of plasma low-density lipoprotein cholesterol, triglycerides, or high-density lipoprotein cholesterol. The task force also recognises the scarcity of qua…

medicine.medical_specialtyRare dyslipidaemiaConsensusSettore MED/09 - Medicina InternaGenotypediagnosisEndocrinology Diabetes and MetabolismMEDLINE030209 endocrinology & metabolism610 Medicine & health03 medical and health sciences0302 clinical medicineEndocrinologyRare DiseasesGenotype540 ChemistryInternal Medicinemedicinegeneome sequencingHumansgeneticsGenetic Predisposition to DiseaseRare dyslipidemias; genetics; diagnosis; treatment030212 general & internal medicineDisease management (health)Intensive care medicineHealth policyDyslipidemias10038 Institute of Clinical Chemistrytreatmentbusiness.industryTask forcegene therapiesDisease ManagementAtherosclerosisPhenotype1310 EndocrinologyEurope2712 Endocrinology Diabetes and MetabolismPhenotype2724 Internal MedicinePractice Guidelines as TopicRare dyslipidemiasEuropean atherosclerosis societylipids (amino acids peptides and proteins)businessQuality information
researchProduct

Issues with European guidelines for phenylketonuria

2017

medicine.medical_specialtybusiness.industryPhenylketonuriasEndocrinology Diabetes and MetabolismMEDLINE610 Medicine & health1310 Endocrinology03 medical and health sciences2712 Endocrinology Diabetes and Metabolism0302 clinical medicineEndocrinology10036 Medical Clinic2724 Internal MedicineFamily medicinePhenylketonuriasInternal MedicineMedicineHumans030212 general & internal medicinebusiness030217 neurology & neurosurgery
researchProduct

Continuous subcutaneous Insulin infusion leads to immediate, table, and long-term changes in metabolic control

2008

Background:  Evaluations of continuous subcutaneous insulin infusion (CSII) usually focus on one pre- and one post-CSII measurement to assess metabolic therapy outcome. Aim:  Extending this research, the aim of the present study was to provide a more fine-grained analysis of achieved glycaemic control. Methods:  In 52 patients with type 1 diabetes (mean age of 37.85 years at CSII begin; s.d. ± 12.41), haemoglobin A1c (HbA1c) levels were assessed every 3 months over a period of 5 years (1 year before and 4 years after the introduction of CSII). Mixed models were utilized to describe changes in glycaemic control. Results:  The pre–post course showed that already in the first quarter, a statis…

mixed modelsAdultBlood GlucoseMalemedicine.medical_specialtyPediatricstype 1 diabetesEndocrinology Diabetes and MetabolismModels BiologicalDrug Administration ScheduleTimeHba1c levelEndocrinologyDiabetes mellitusInternal Medicinemedicinefollow upHumansHypoglycemic AgentsInsulinAge of OnsetGlycated HemoglobinType 1 diabetesHaemoglobin A1cbusiness.industry10093 Institute of PsychologyCSIIMean ageInfusion Pumps ImplantableMiddle AgedPrognosismedicine.diseaseSubcutaneous insulinSurgery1310 Endocrinologylong-term changes2712 Endocrinology Diabetes and MetabolismDiabetes Mellitus Type 1Treatment Outcome2724 Internal MedicineMetabolic control analysisFemalebusiness150 PsychologyFollow-Up StudiesMetabolic therapy
researchProduct